Pulmonary arterial hypertension associated with congenital heart disease

Progress in Pediatric Cardiology

Volumn 27, Issue 1-2, 2009, Pages 25-33

  Kulik, Tom ^a   Mullen, Mary ^a   Adatia, Ian ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b STOLLERY CHILDREN S HOSPITAL   (Canada)

Author keywords

Congenital heart disease; Pulmonary arterial hypertension; Pulmonary vascular resistance

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; NIFEDIPINE; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; WARFARIN;

ARTERY LESION; ARTERY RECONSTRUCTION; CARDIOPULMONARY HEMODYNAMICS; CHILD CARE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EISENMENGER COMPLEX; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HISTOPATHOLOGY; HUMAN; LUNG ARTERY BANDING; LUNG ARTERY PRESSURE; LUNG BIOPSY; LUNG BLOOD FLOW; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MEDICAL DECISION MAKING; NONHUMAN; OXYGEN THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SURGICAL RISK;

EID: 70649115363     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2009.09.005     Document Type: Review

References (149)

1. Adatia I. Pulmonary vascular disease. In: Freedom R.M., Yoo S.-J., Mikailian H., and Williams W.G. (Eds). The natural and modified history of congenital heart disease (2004), Futura, New York 518
2. Tefuarini N., Hawker R., Vince J., Sleigh A., and Williams G.M. Surgical programme at Royal Alexandria Hospital, Sydney, for Papua New Guinea children with congenital heart disease, 1978-1994. J Paediatr Child Health 38 (2002) 178-182
3. Butrous G., Ghofrani H.A., and Grimminger F. Pulmonary vascular disease in the developing world. Circulation 118 17 (Oct 21 2008) 1758-1766
4. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 12 Suppl S (Jun 16 2004) 5S-12S
5. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54 (2009) S43-S54
6. Lee S.-D., Shroyer K.R., Markham N.E., Cool C.D., Voelkel N.F., and Tuder R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101 (1998) 927-934
7. Roberts K.E., McElroy J.J., Wong W.P., et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 24 3 (2004 Sep) 371-374
8. Harrison R.E., Berger R., Haworth S.G., et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 111 4 (Feb 1 2005) 435-441
9. Wood P. The eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ (Clinical research ed.) 2 (1958) 701-709
10. Shepherd J.T., Semler H.J., Helmholz H.F., and Wood E.H. Effects of infusion of acetylcholine on pulmonary vascular resistance in patients with pulmonary hypertension and congenital heart disease. Circulation 20 (1959) 381-390
11. Swan H.J.C., Burchell H.B., and Wood E.H. Effect of oxygen on pulmonary vascular resistance in patients with pulmonary hypertension associated with atrial septal defect. Circulation 20 (1959) 66-73
12. Vogel J.H., Grover R.F., Jamieson G., and Blount Jr. S.G. Long-term physiologic observations in patients with ventricular septal defect and increased pulmonary vascular resistance (with 2 color plates). Adv Cardiol 11 00 (1974) 108-122
13. Wessel D.L., Adatia I., Giglia T.M., Thompson J.E., and Kulik T.J. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. part 1. Circulation 88 (1993) 2128-2138
14. Neutze J.M., Ishikawa T., Clarkson P.M., Calder A.L., Barratt-Boyes B.G., and Kerr A.R. Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance. Am J Cardiol 63 5 (Feb 1 1989) 327-331
15. Bush A., Busst C., Booth K., Knight W.B., and Shinebourne E.A. Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease?. Circulation 74 1 (1986) 135-144
16. Brammell H.L., Vogel J.H.K., Pryor R., and Blount S.G. The Eisenmenger syndrome a clinical and physiological reappraisal. Am J Cardiol 28 (1971) 679-692
17. Bowyer J.J., Busst C.M., Denison D.M., and Shinebourne E.A. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 55 (1986) 385-390
18. Post M.C., Janssens S., Van de Werf F., and Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J 25 18 (Sep 2004) 1651-1656
19. Auld P.A.M., Gibbons J.E., and McGregor M. Vasomotor tone in the pulmonary vascular bed in patients with left to right shunts. Br Heart J 25 (1963) 257-261
20. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 20 (1958) 557-570
21. Heath D., and Edwards J.E. The pathology of hypertensive pulmonary vascular disease. Circulation 28 (1958) 533-547
22. Rabinovitch M., Haworth S., Castaneda A., Nadas A., and Reid L. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 58 (1978) 1107-1122
23. Haworth S.G. Pulmonary vascular disease in ventricular septal defect: structural and functional correlations in lung biopsies from 85 patients, with outcome of intracardiac repair. J Pathol 152 3 (Jul 1987) 157-168
24. Haworth S.G., and Hislop A.A. Pulmonary vascular development: normal values of peripheral vascular structure. Am J Cardiol 52 5 (Sep 1 1983) 578-583
25. Eisenmenger V. Die angeborenes Defekt der Kammerschiedewand des Herzen. Z Klin Med Suppl 32 (1897) 1-28
26. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ (Clinical research ed.) 2 (1958) 755-762
27. Adatia I., Perry S., Landzberg M., Moore P., Thompson J.E., and Wessel D.L. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol 25 7 (1995) 1652-1664
28. Budts W., Pelt N.V., Gillyns H., Gewillig M., Werf F.V.d., and Janssens S. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart (British Cardiac Society) 86 (2001) 553-558
29. Rabinovitch M., Keane J.F., Norwood W.I., Castaneda A.R., and Reid L. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 69 4 (Apr 1984) 655-667
30. Hoffman J., Rudolph A., and Heymann M. Pulmonary vascular disease with congenital heart lesions; pathological features and causes. Circulation 64 (1981) 873-877
31. Epting C.J., Wolfe R.R., Abman S.H., Deutsch G.H., and Ivy D. Reversal of pulmonary hypertension associated with plexiform lesions in congenital heart disease; a case report. Pediatr Cardiol 23 (2002) 182-185
32. Weidman W., Blount S., DuShane J., Gersony W., Hayes C., and Nadas A. Clinical course in ventricular septal defect. Circulation 56 Suppl l (1977) I-56-69
33. Dexter L. Atrial septal defect. Br Heart J 18 2 (Apr 1956) 209-225
34. Craig R.J., and Selzer A. Natural history and prognosis of atrial septal defect. Circulation 37 5 (May 1968) 805-815
35. Besterman E. Atrial septal defect with pulmonary hypertension. Br Heart J 23 (1961) 587-598
36. Goetschmann S., Dibernardo S., Steinmann H., Pavlovic M., Sekarski N., and Pfammatter J.P. Frequency of severe pulmonary hypertension complicating "isolated" atrial septal defect in infancy. Am J Cardiol 102 3 (Aug 1 2008) 340-342
37. Haworth S.G. Pulmonary vascular disease in secundum atrial septal defect in childhood. Am J Cardiol 51 (1982) 265-272
38. Steele P.M., Fuster V., Cohen M., Ritter D.G., and McGoon D.C. Isolated atrial septal defect with pulmonary vascular obstructive disease-long term follow up and prediction of outcome after surgical correction. Circulation 76 5 (1987) 1037-1042
39. Cherian G., Uthaman C.B., Durairaj M., et al. Pulmonary hypertension in isolated secundum atrial septal defect: high frequency in young patients. Am Heart J 105 (1983) 952-957
40. Yamaki S., Horiuchi T., Miura M., Suzuki Y., Ishizawa E., and Takahashi T. Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension. Chest 89 5 (1986) 694-698
41. Bull C., Deanfield J., de Leval M., Stark J., Taylor J.F., and Macartney F.J. Correction of isolated secundum atrial septal defect in infancy. Arch Dis Child 56 10 (Oct 1981) 784-786
42. Manning P.B., Mayer Jr. J.E., Sanders S.P., et al. Unique features and prognosis of primum ASD presenting in the first year of life. Circulation 90 5 Pt 2 (Nov 1994) II30-II35
43. Yeager S.B., Freed M.D., Keane J.F., Norwood W.I., and Castaneda A.R. Primary surgical closure of ventricular septal defect in the first year of life: results in 128 infants. J Am Coll Cardiol 3 5 (May 1984) 1269-1276
44. Clarkson P.M., Frye R.L., DuShane J.W., Burchell H.B., Wood E.H., and Weidman W.H. Prognosis for patients with ventricular septal defect and severe pulmonary vascular disease. Circulation 38 (1968) 129-135
45. Friedli B., Kidd B.L., Mustard W., and Keith J. Ventricular septal defect with increased pulmonary vascular resistance. Am J Cardiol 33 (1974) 403-409
46. Cartmill T., DuShane J., McGoon D., and Kirklin J. Results of repair of ventricular septal defect. J Thorac Cardiovasc Surg 52 4 (1966) 486-501
47. Castañeda A.R., Zamora R., Nicoloff D.M., Moller J.H., Hunt C.E., and Lucas R.V. High-pressure, high resistance ventricular septal defect. Ann Thorac Surg 12 (1971) 29-36
48. Sigmann J.M., Perry B.L., Gehrendt D.M., Stern A.M., Kirsh M.M., and Sloan H.E. Ventricular septal defect: results after repair in infancy. Am J Cardiol 39 1 (Jan 1977) 66-71
49. Hallidie-Smith K.A., Hollman A., Cleland W.P., Bentall H.H., and Goodwin J.F. Effects of surgical closure of ventricular septal defects upon pulmonary vascular disease. Br Heart J 31 2 (Mar 1969) 246-260
50. Kidd L., Rose V., Collins G., and Keith J. The hemodynamics in ventricular septal defect in childhood. Am Heart J 70 6 (Dec 1965) 732-738
51. Keith J. Ventricular septal defect. In: Keith J., Vlad P., and Rowe R.D. (Eds). Heart disease in infancy and childhood (1978), Macmillan Publishing Co, New York 320-379
52. Moller J.H., Patton C., Varco R.L., and Lillehei C.W. Late results (30 to 35) years after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol 68 (1991) 1491-1497
53. Lueker R.D., Vogel J.H., and Blount Jr. S.G. Cardiovascular abnormalities following surgery for left-to-right shunts. Observations in atrial septal defects, ventricular septal defects, and patent ductus arteriosus. Circulation 40 6 (Dec 1969) 785-801
54. Wallgren C.G., Boccanelli A., Zetterqvist P., and Bjork V.O. Late results after surgical closure of ventricular septal defect in children. Scand J Thorac Cardiovasc Surg 14 2 (1980) 145-151
55. Ikawa S., Shimazaki Y., Nakano S., Kobayashi J., Matsuda H., and Kawashima Y. Pulmonary vascular resistance during exercise late after repair of large ventricular septal defects. Relation to age at the time of repair. J Thorac Cardiovasc Surg 109 6 (Jun 1995) 1218-1224
56. Hallidie-Smith K.A., Wilson R.S., Hart A., and Zeidifard E. Functional status of patients with large ventricular septal defect and pulmonary vascular disease 6 to 16 years after surgical closure of their defect in childhood. Br Heart J 39 10 (Oct 1977) 1093-1101
57. Kulik T.J., Bass J.L., Fuhrman B.P., Moller J.H., and Lock J.E. Exercise induced pulmonary vasoconstriction. Br Heart J 50 1 (Jul 1983) 59-64
58. Maron B.J., Redwood D.R., Hirshfeld Jr. J.W., Goldstein R.E., Morrow A.G., and Epstein S.E. Postoperative assessment of patients with ventricular septal defect and pulmonary hypertension. Response to intense upright exercise. Circulation 48 4 (Oct 1973) 864-874
59. Kannan B.R., Sivasankaran S., Tharakan J.A., et al. Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. Indian Heart J 55 2 (Mar-Apr 2003) 161-166
60. Haworth S.G. Pulmonary vascular disease in different types of congenital heart disease. Br Heart J 52 (1984) 557-571
61. Clarkson P.M., Neutze J.M., Wardill J.C., and Barratt-Boyes B.G. The pulmonary vascular bed in patients with complete transposition of the great arteries. Circulation 53 3 (Mar 1976) 539-543
62. Lakier J.B., Stanger P., Heymann M.A., Hoffma N.J., and Rudolph A.M. Early onset of pulmonary vascular obstruction in patients with aortopulmonary transposition and intact ventricular septum. Circulation 51 5 (May 1975) 875-880
63. Keane J.F., Ellison R.C., Rudd M., and Nadas A.S. Pulmonary blood flow and left ventricular volumes in transposition of the great arteries and intact ventricular septum. Br Heart J 35 5 (May 1973) 521-526
64. Newfeld E.A., Paul M.H., Muster A.J., and Idriss F.S. Pulmonary vascular disease in transposition of the great vessels and intact ventricular septum. Circulation 59 3 (Mar 1979) 525-530
65. Sreeram N., Petros A., Peart I., and Arnold R. Progressive pulmonary hypertension after the arterial switch procedure. Am J Cardiol 73 (1994) 620-621
66. Rivenes S.M., Grifka R.G., and Feltes T.F. Development of advanced pulmonary vascular disease in D-transposition of the great arteries after the neonatal arterial switch operation. Tex Heart Inst J 25 3 (1998) 201-205
67. Kumar A., Taylor G., Sandor G., and Patterson M. Pulmonary vascular disease in neonates with transposition of the great arteries and intact ventricular septum. Br Heart J 69 (1993) 442-445
68. Maeno Y., Hornberger L.K., Kamenir S.A., Sinclair B., and Smallhorn J.F. Prenatal features of restrictive foramen ovale and ductal constriction in D-transposition of the great arteries. Circulation I-129 (1997) 724A
69. Soongswang J., Adatia I., Newman C., Smallhorn J.F., Williams W.G., and Freedom R.M. Mortality in potential arterial switch candidates with transposition of the great arteries. J Am Coll Cardiol 32 (1998) 753-757
70. Rudolph A. Congenital diseases of the heart: clinical-physiological considerations (2001), Futura, Armonk, New York 703
71. Juaneda E., and Haworth S.G. Pulmonary vascular disease in children with truncus arteriosus. Am J Cardiol 54 10 (Dec 1 1984) 1314-1320
72. Mair D.D., Ritter D.G., Davis G.D., Wallace R.B., Danielson G.K., and McGoon D.C. Selection of patients with truncus arteriosus for surgical correction. Circulation 49 (1974) 144-151
73. Agarwala B., Waldman J.D., Sand M., Loe W.A., and Ruschhaupt D.G. Aortic origin of the RPA: immediate resolution of severe pulmonary artery hypertension by surgical repair. Pediatr Cardiol 15 (1994) 41-44
74. Freedom R.M., Yoo S.-J., and Coles J.G. Atrioventricular septal defect. In: Freedom R.M., Yoo S.-J., Mikailian H., and Williams W.G. (Eds). The natural and modified history of congenital heart disease (2004), Futura, New York
75. Cooney T.P., and Thurlbeck W.M. Pulmonary hypoplasia in Down's syndrome. N Engl J Med 307 (1982) 1170-1173
76. Marino B. Patterns of congenital heart disease and associated cardiac anomalies in children with Down syndrome. In: Marino B., and Pueschel S.M. (Eds). Heart disease in persons with Down syndrome (1996), Paul H Brookes Publishing Co, Baltimore, Maryland 133-140
77. Vogel J.H., McNamara D.G., and Blount Jr. S.G. Role of hypoxia in determining pulmonary vascular resistance in infants with ventricular septal defects. Am J Cardiol 20 3 (Sep 1967) 346-349
78. Chen Q.H., Wang X.Q., and Qi S.G. Cross-sectional study of congenital heart disease among Tibetan children aged from 4 to 18 years at different altitudes in Qinghai Province. Chin Med J (Engl) 121 24 (Dec 20 2008) 2469-2472
79. Miao C.Y., Zuberbuhler J.S., and Zuberbuhler J.R. Prevalence of congenital cardiac anomalies at high altitude. J Am Coll Cardiol 12 1 (Jul 1988) 224-228
80. Penaloza D., Arias-Stella J., Sime F., Recavarren S., and Marticorena E. The heart and pulmonary circulation in children at high altitudes: physiological, anatomical, and clinical observations. Pediatrics 34 (Oct 1964) 568-582
81. Niermeyer S. Cardiopulmonary transition in the high altitude infant. High Alt Med Biol 4 2 (Summer 2003) 225-239
82. Sime F., Banchero N., Peñaloza D., Gamboa R., Cruz J., and Marticorena E. Pulmonary hypertension in children born and living at high altitudes. Am J Cardiol 11 (1963) 143-149
83. Williams D. Adaptation and acclimatisation in humans and animals at high altitude. Thorax 49 (1994) S9-S13
84. Penaloza D., and Arias-Stella J. The heart and pulmonary circulation at high altitudes:helthyhighlanders and chronic moutain sickness. Circulation 115 (2007) 1132-1146
85. Langille B.L. Arterial remodeling: relation to hemodynamics. Can J Physiol Pharmacol 74 7 (Jul 1996) 834-841
86. Li C., and Xu Q. Mechanical stress-initiated signal transduction in vascular smooth muscle cells in vitro and in vivo. Cell Signal 19 5 (May 2007) 881-891
87. Reddy V.M., Meyrick B., Wong J., et al. In utero placement of aortopulmonary shunts. A model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs. Circulation 92 3 (Aug 1 1995) 606-613
88. Mata-Greenwood E., Meyrick B., Steinhorn R.H., Fineman J.R., and Black S.M. Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 285 1 (Jul 2003) L209-L221
89. Mata-Greenwood E., Meyrick B., Soifer S.J., Fineman J.R., and Black S.M. Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 285 1 (Jul 2003) L222-L231
90. Black S.M., Bekker J.M., Johengen M.J., Parry A.J., Soifer S.J., and Fineman J.R. Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 47 1 (Jan 2000) 97-106
91. Wedgwood S., Devol J.M., Grobe A., et al. Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 61 1 (Jan 2007) 32-36
92. Botney M.D. Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Am J Respir Crit Care Med 159 2 (Feb 1999) 361-364
93. Rabinovitch M., Konstam M.A., Gamble W.J., et al. Changes in pulmonary blood flow affect vascular response to chronic hypoxia in rats. Circ Res 52 4 (Apr 1983) 432-441
94. O'Blenes S.B., Fischer S., McIntyre B., Keshavjee S., and Rabinovitch M. Hemodynamic unloading leads to regression of pulmonary vascular disease. J Thorac Cardiovasc Surg 121 (2001) 279-289
95. Adatia I., Barrow S., Stratton P., Ritter J., and Haworth S. Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt. Br Heart J 72 (1994) 452-456
96. Adatia I., Barrow S.E., Stratton P., Miall-Allen V.M., Ritter J.M., and Haworth S.G. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 88 (1993) 2117-2122
97. Stewart D., Levy R., Cernacek P., and Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease. Ann Intern Med 114 (1991) 464-469
98. Komai H., Adatia I., Elliott M.J., Leval M.R.d., and Haworth S.G. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg. 106 (1993) 473-478
99. Gorenflo M., Gross P., Bodey A., et al. Plasma endothelin-1 in patients with left-to-right shunt. Am Heart J 130 (1995) 537-542
100. Yoshibayashi M., Nishioka K., Nakao K., et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 84 6 (Dec 1991) 2280-2285
101. Adatia I., and Haworth S.G. Circulating endothelin in children with congenital heart disease. Br Heart J 69 (1993) 233-236
102. Yamamoto K., Ikeda U., Mito H., Fujikawa H., Sekiguchi H., and Shimada K. Endothellin production in pulmonary circulation of patients with mitral stenosis. Circulation 89 (1994) 2093-2098
103. Feinstein J.A. Evaluation, risk stratification, and management of pulmonary hypertension in patients with congenital heart disease. Semin. Thorac. Cardiovasc. Surg. 12 (2009) 106-111
104. Jones O.D.H., Shore D.F., Rigby M.L., et al. The use of tolazoline hydrochloride as a pulmonary vasodilator in potentially fatal episodes of pulmonary vasoconstriction after cardiac surgery in children. Circulation 64 Suppl II (1981) II-134-II-9
105. Hopkins R.A., Bull C., Haworth S.G., Leval M.R., and Stark J. Pulmonary hypertensive crises following surgery for congenital heart defects in young children. Eur J Cardiothorac Surg 5 (1991) 628-634
106. Balzer D.T., Kort H.W., Day R.W., et al. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group. Circulation 106 12 Suppl 1 (Sep 24 2002) I76-I81
107. Lock J.E., Einzig S., Bass J.L., and Moller J.H. The pulmonary vascular response to oxygen and its influence on operative results in children with ventricular septal defect. Pediatr Cardiol 3 (1982) 41-46
108. Dammann Jr. J.F., MCeachen J.A., Thompson Jr. W.M., Smith R., and Muller Jr. W.H. The regression of pulmonary vascular disease after the creation of pulmonary stenosis. J Urol Nephrol (Paris) 42 (Dec 1961) 722-734
109. Wagenvoort C.A., Wagenvoort N., and Draulans-Noë Y. Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery. J Thorac Cardiovasc Surg 87 (1984) 876-886
110. Azzolina G. Discussion of high pressure, high resistance ventricular septal defect surgical results of closure through right atrium. J Thorac Cardiovasc Surg 12 (1971) 37
111. Batista R.J.V., Santos J.L.V., Takeshita N., et al. Successful reversal of pulmonary hypertension in Eisenmenger complex. Arq Bras Cardiol 68 (1997) 279-280
112. Novick W.M., Gurbuz A.T., Watson D.C., et al. Double patch closure of ventricular septal defect with increased pulmonary vascular resistance. Ann Thorac Surg 66 (1998) 1533-1538
113. Novick W.M., Sandoval N., Lazorhysynets V.V., et al. Flap valve double patch closure of ventricular septal defects in children with increased pulmonary vascular resistance. discussion -8. Ann Thorac Surg 79 1 (Jan 2005) 21-28
114. Sandoval J., Alvarado P., Martinez-Guerra M.L., et al. Effect of body position changes on pulmonary gas exchange in Eisenmenger's syndrome. Am J Respir Crit Care Med 159 4 Pt 1 (Apr 1999) 1070-1073
115. Sandoval J., Aguire J.S., Pulido T., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 164 (2001) 1682-1687
116. Kulik T.J. Inhaled nitric oxide in the management of congenital heart disease. Curr Opin Cardiol 11 1 (Jan 1996) 75-80
117. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
118. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 23 (Jun 14 2005) 3105-3111
119. Barst R.J., McGoon M., Torbicki A., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43 12 Suppl S (Jun 16 2004) 40S-47S
120. Wong C.K., Yeung D.W., Lau C.P., Cheng C.H., and Leung W.H. Improvement of exercise capacity after nifedipine in patients with Eisenmenger syndrome complicating ventricular septal defect. Clin Cardiol 14 12 (Dec 1991) 957-961
121. Wimmer M., and Schlemmer M. Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children. Cardiovasc Drugs Ther 6 2 (Apr 1992) 183-186
122. Rosenzweig E.B., Kerstein D., and Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99 (1999) 1858-1865
123. Fernandes S.M., Newburger J.W., Lang P., et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 91 5 (Mar 1 2003) 632-635
124. Galiè N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 1 (Jul 4 2006) 48-54
125. D'Alto M., Vizza C.D., Romeo E., et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart (British Cardiac Society) 93 5 (May 2007) 621-625
126. Gatzoulis M.A., Beghetti M., Galie N., et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 127 1 (Jun 23 2008) 27-32
127. van Loon R.L., Hoendermis E.S., Duffels M.G., et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?. Am Heart J 154 4 (Oct 2007) 776-782
128. Apostolopoulou S.C., Manginas A., Cokkinos D.V., and Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart (British Cardiac Society) 91 11 (Nov 2005) 1447-1452
129. Apostolopoulou S.C., Manginas A., Cokkinos D.V., and Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart (British Cardiac Society) 93 3 (Mar 2007) 350-354
130. Sitbon O., Beghetti M., Petit J., et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest 36 Suppl 3 (Sep 2006) 25-31
131. Kourouklis S., Christopoulos A., Liagkas K., Paradellis G., and Kyriakides Z.S. Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension. Eur J Clin Invest 36 Suppl 3 (Sep 2006) 39-43
132. Diller G.P., Dimopoulos K., Kaya M.G., et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart (British Cardiac Society) 93 8 (Aug 2007) 974-976
133. Benza R.L., Rayburn B.K., Tallaj J.A., et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest 129 4 (Apr 2006) 1009-1015
134. Christensen D.D., McConnell M.E., Book W.M., and Mahle W.T. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 94 2 (Jul 15 2004) 261-263
135. Durongpisitkul K., Jakrapanichakul D., and Sompradikul S. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 91 2 (Feb 2008) 196-202
136. Kotlyar E., Sy R., Keogh A.M., et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Cardiol Young 16 3 (Jun 2006) 268-274
137. Schulze-Neick I., Gilbert N., Ewert R., et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 150 4 (Oct 2005) 716
138. Duffels M.G., Vis J.C., van Loon R.L., et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option?. Int J Cardiol (Jun 23 2008)
139. Beghetti M., Hoeper M.M., Kiely D.G., et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 64 2 (Aug 2008) 200-204
140. Rosenzweig E.B., Ivy D.D., Widlitz A., et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46 4 (2005) 697-704
141. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
142. Barst R.J., Langleben D., Badesch D., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 10 (May 16 2006) 2049-2056
143. Benza R.L., Barst R.J., Galie N., et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 134 4 (Oct 2008) 775-782
144. Maiya S., Hislop A.A., Flynn Y., and Haworth S.G. Response to bosentan in children with pulmonary hypertension. Heart (British Cardiac Society) 92 5 (May 2006) 664-670
145. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation 105 (2002) 2398-2403
146. Michelakis E.D., Tymchak W., Noga M., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108 (2003) 2066-2069
147. Chau E.M., Fan K.Y., and Chow W.H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 120 3 (Sep 3 2007) 301-305
148. Humpl T., Reyes J.T., Holtby H., Stephens D., and Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation (Jun 13 2005)
149. Wort S.J. Sildenafil in Eisenmenger syndrome: safety first. Int J Cardiol 120 3 (Sep 3 2007) 314-316